Inverness Counsel’s Amgen AMGN Stock Holding History

Inverness Counsel’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$351K	Buy	+1,556	New	+$377K	0.02%	147

Other funds holding AMGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Inverness Counsel's AMGN Position: Q3 2022 in Review

Inverness Counsel opened a new position in Amgen (AMGN) in Q3 2022: 1,556 shares worth $351K. The stake represents 0.02% of the portfolio and ranks #147 among its holdings.

2,323 funds tracked by Wall St. Rank hold AMGN as of Q3 2022.

Inverness Counsel held 1,556 shares of Amgen worth $351K as of Q3 2022.
Amgen was a new Inverness Counsel position in Q3 2022.
Amgen made up 0.02% of Inverness Counsel's portfolio in Q3 2022, its #147 holding.
2,323 funds tracked by Wall St. Rank held Amgen as of Q3 2022.

Based on Inverness Counsel's 13F filing for Q3 2022, filed 26 Oct 2022.